SERA
Sera Prognostics, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$2.03-0.98%
Price as of Jul 20, 2026
SERA growth
Sera Prognostics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -50.4%
- EBITDA
- +2.8%
- EBIT
- +0.5%
- EPS
- +30.9%
- Free cash flow
- -1.6%
- Operating cash flow
- -0.4%
Forward estimates
- Revenue
- —
- EBITDA
- +59.9%
- EPS
- +16.5%
Three-year CAGR
- Revenue
- -32.9%
- EBITDA
- +3.3%
- EBIT
- +0.4%
- Net income
- +2.9%
- EPS
- +32.3%
- Free cash flow
- -72.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.